Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT00882869 is registered in ClinicalTrials.gov with Aegera Therapeutics as lead sponsor.

NCT NCT00882869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00882869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Aegera Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2009
Completion date
May 31, 2011
Enrollment
75 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma